Media Coverage

Nexvet signs Pfizer antibody deal, net loss narrows

Feb 10, 2017 - Animal Pharm

By Joseph Harvey
Animal Pharm
February 10, 2017

Nexvet Biopharma has entered into a license agreement with Pfizer relating to anti-nerve growth factor (NGF) antibodies.

Under the terms of the deal, Nexvet has received a non-exclusive license to certain patents in the Pfizer portfolio for anti-NGF antibodies.

Dublin, Ireland-headquartered Nexvet will pay Pfizer a $1 million upfront license fee and may pay additional amounts based on regulatory and sales milestones. The firm may also pay Pfizer "a low, single-digit royalty based on net sales of the company's anti-NGF product candidates for the life of the relevant patents".

Ranevetmab is Nexvet's PETized monoclonal antibody designed to inhibit the activity of canine NGF. The company is developing ranevetmab as a treatment to control pain associated with canine osteoarthritis.

This is not the first time Nexvet has struck a deal with a big player in the human health sector. In November 2016, the firm entered into a research collaboration with Genentech. This deal involves use of the Company’s PETization platform.  The two partners will conduct a proof-of-concept study, which will be funded by Genentech.

Q2 shows smaller net loss

Nexvet has reported a slightly smaller net loss in its second fiscal quarter of 2017

For the three months ended December 31, 2016, the firm recorded a net loss of $5.4m, compared to $5.7m loss in the same period of 2015. The latest net loss included operating expenses of $5.2m, including $3.8m in R&D costs and $1.4m in general expenditure.

Over the six-month period, Nexvet witnessed a net loss of $10.5m. This was greater than the $9.7m loss in the first six months of fiscal 2016. While the company recorded smaller R&D and general costs, it suffered from an exchange loss of $1m.

"This was an important period of progress for the company as we initiated pivotal clinical studies for frunevetmab, continued to advance our chemistry, manufacturing and controls activities, and entered into a collaboration with Genentech, our first such agreement with a dedicated human biotech company utilizing our PETization platform," said Mark Heffernan, chief executive of Nexvet.

Reprinted with permission of Animal Pharm News 







Selection Committee

Judging Panel


Conference Materials

Business Partnering

Venue/ Accommodations